Gliknik Stock
Gliknik develops therapies for patients with cancer and immune disorders.
Sign up today and learn more about Gliknik Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Gliknik Stock
Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the efficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to monocolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.
Investors
Pfizer
Funding History
| January 2010 | $2.9M |
|---|---|
| September 2010 | $2.4M |
| January 2011 | $3.5M |
| September 2011 | $2.0M |
| October 2012 | $4.9M |
| May 2013 | $20.0M |
| September 2013 | $2.8M |
| February 2019 | $15.0M |
Management
Founder, President and CEO
David S. Block
Founder & Scientist
Scott E. Strome
Press
technical - Dec, 23 2023
Baltimore's Q3 Venture Monitor report is out. An expert thinks ...bizjournals - Dec, 23 2023
Baltimore pharmaceutical company raising $16M to combat ...Yahoo Finance - Feb, 19 2019
Gliknik To Receive $15 Million Milestone Payment From Pfizer Inc. Following Clinical Progress With PF-06755347, Previously Known As GL-2045PR Newswire - Apr, 3 2018
Gliknik Announces Issuance of U.S. Patent for Use of Recombinant IVIG MimeticsEquityZen Recognized As:
